Although there is minimal evidence that HER2 status predicts NENs, there is a case report in the literature of the success of trastuzumab treatment in a patient with NEC and HER2 amplification of the breast [81]. This evidence concerns the gene ERBB2 and neuroendocrine carcinoma.